ENTREGA (Oral Administration of Biologics – Novel Hydrogel)

(ENT101)

GI System

TRIAL PHASE
AFFILIATEFOCUSPRTC
OWNERSHIP
PRECLINICALPHASE 1PHASE 2PHASE 3/
PIVOTAL
FILINGFDA CLEARED
Entrega
Engineered Hydrogels to Enable Oral Delivery of Peptides
73.9%

GI System

Entrega
Engineered Hydrogels to Enable Oral Delivery of Peptides
73.9%
Preclinical
Enabling the delivery of biologics via the gut epithelium to local and distal sites of the body.

Founded by PureTech Health, Entrega is focused on the oral delivery of biologics, vaccines, and other drugs that are otherwise not efficiently absorbed when taken orally. The vast majority of biologic drugs (including peptides, proteins, and other macromolecules) are currently administered by injection, which can present challenges for healthcare delivery and compliance with treatment regimes. Oral administration thus represents an ideal delivery approach for this increasingly large class of therapies reshaping many areas of medicine, including the treatment of diabetes.

Our technology platform is an innovative approach to oral delivery which uses a proprietary, customizable hydrogel dosage form to control local fluid microenvironments in the GI tract to both enhance absorption and reduce the variability of drug exposure. To validate our technology, we generated proof-of-concept data demonstrating delivery of therapeutic peptides into the bloodstream of large animals.

  • Patient Need & Market Potential
    • The total global biologics market could be close to $400 billion by 2025.
    • Injectable formulations can be limited in their therapeutic potential as a result of issues with compliance, and they can be difficult and potentially unsafe to deliver to patients.
  • Our Approach to Solving the Problem
    • The Entrega platform is designed to enable oral delivery of biologics, vaccines and other forms of medication that are not efficient in reaching the bloodstream when taken orally.
  • Intellectual Property
    • Entrega has broad intellectual property coverage worldwide, including nineteen (19) patent applications in six (6) families of patent filings.
    • Entrega’s patent portfolio covers oral drug devices, drug formulations, compositions of matter, methods of use, and methods of making hydrogel dosage forms for delivery of active agents.
  • Team
    • The Entrega team is comprised of experts in drug formulation and drug delivery engineering.
    • Key advisors include Dr Robert Langer (PureTech Health and MIT), Dr Colin Gardner (previously TransForm Pharmaceuticals, Johnson & Johnson, and Merck), Dr Samir Mitragotri (Wyss Institute at Harvard University, previously UC Santa Barbara), Mr Rob Armstrong (Boston Pharmaceuticals and previously Eli Lilly), and Mr Howie Rosen (previously ALZA Corporation)
  • Collaborations
    • Entrega received $5 million in equity and research funding from Eli Lilly to investigate the application of its peptide delivery technology to certain Lilly therapeutic candidates.
  • Milestones Achieved
    • Entrega has generated proof-of-concept data demonstrating successful delivery of peptides in large animals.

Entrega’s technology platform is an innovative approach to oral delivery which uses a proprietary, customizable hydrogel dosage form to control local fluid microenvironments in the GI tract to both enhance absorption and reduce the variability of drug exposure. To validate its technology, Entrega generated proof-of-concept data demonstrating delivery of therapeutic peptides into the bloodstream of large animals.